Plus Therapeutics, Inc. provided revenue guidance for the fourth quarter of 2023 and calendar year of 2024. The company forecasts grant revenue of between $1 million to $1.5 million in fourth quarter of 2023 and between $6 million to $7 million for calendar year 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.14 USD | -0.93% | -4.46% | +22.28% |
May. 15 | Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
May. 09 | Transcript : Plus Therapeutics, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.28% | 12.21M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- PSTV Stock
- News Plus Therapeutics, Inc.
- Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024